AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.